摘要
目的分析坦洛新与铍针联合治疗慢性前列腺炎(CP)所致性功能障碍的临床效果。方法将90例CP所致性功能障碍患者按照随机数字表法分为对照组与研究组,各45例。对照组患者给予坦洛新治疗,研究组患者给予坦洛新联合铍针疗法治疗,均治疗4周。比较治疗前后两组患者慢性前列腺炎症状指数(NIH-CPSI)评分、国际勃起功能指数(IIEF-5)评分、中国早泄患者性功能评价表-5(CIPE-5)评分及血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)水平。比较两组患者治疗后的临床治疗总有效率。结果治疗后,研究组患者NIH-CPSI总分及各维度评分,TNF-α、IL-6、IL-8、IL-10水平均低于对照组,IIEF-5评分、CIPE-5评分及临床治疗总有效率均高于对照组(P<0.05或0.01)。结论坦洛新联合铍针疗法治疗可显著改善CP所致性功能障碍患者的临床症状及性功能,临床效果优于单用坦洛新治疗。
Objective To analyze the clinical effect of tamsulosin plus stiletto needle therapy(ANT)on sexual dysfunction caused by chronic prostatitis(CP).Methods Ninety patients with CP-caused sexual dysfunction were assigned to research and control group according to random number table method,with 45 ones in each.Control received tamsulosin treatment and research group did tamsulosin plus the SNT for 4 weeks.Before and after treatment such indexes were compared between two groups as scores on the NIH-Chronic Prostatitis Symptom Index(NIH-CPSI),International Index of Erectile Function(IIEF-5)and Chinese Index of Sexual Function for Premature Ejaculation-5(CIPE-5)as well as serum tumor necrosis factor-α(TNF-α),interleukin 6(IL-6),interleukin-8(IL-8)and interleukin-10(IL-10)level.Intergroup total effective rates of clinical treatment were compared.Results After treatment the total and each dimension score of the NIH-CPSI as well as TNF-α,IL-6,IL-8 and IL-10 level were all lower in research than control group;the IIEF-5 and CIPE-5 score as well as the total effective rate of clinical treatment all higher in research than control group(P<0.05 or 0.01).Conclusion Tamlosin combined with the SNT can significantly improve the clinical symptoms and sexual function of patients with CP-induced sexual dysfunction and the clinical effect is better than tamlosin alone.
作者
赵阳
常富江
刘惠明
张楠
单中杰
Zhao Yang;Chang Fujiang;Liu Huiming;Zhang Nan;Shan Zhongjie(Zhengzhou People's Hospital(The Fifth Clinical Medical College of Henan University of Traditional Chinese Medicine),Zhengzhou 450000,Henan,China)
出处
《临床心身疾病杂志》
CAS
2023年第6期121-125,共5页
Journal of Clinical Psychosomatic Diseases
基金
河南省医学科技攻关计划(编号LHGJ20191077)。
